We are live on ! Find out more
IBRX icon

ImmunityBio
IBRX

149 hedge funds and large institutions have $200M invested in ImmunityBio in 2022 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 44 increasing their positions, 39 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

45% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 20

13% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 39

6% more funds holding

Funds holding: 141 → 149 (+8)

0.28% more ownership

Funds ownership: 8.67% → 8.95% (+0.28%)

5% less capital invested

Capital invested by funds: $209M → $200M (-$9.54M)

45% less call options, than puts

Call options by funds: $2.39M | Put options by funds: $4.31M

Holders
149
Holders Change
+8
Holders Change %
+5.67%
% of All Funds
2.35%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
29
Increased
44
Reduced
39
Closed
20
Calls
$2.39M
Puts
$4.31M
Net Calls
-$1.92M
Net Calls Change
+$2.51M

Top Buyers

1
Morgan Stanley
Morgan Stanley
New York
+$3.93M
2
State Street
State Street
Massachusetts
+$3.34M
3
OIM
Oracle Investment Management
Connecticut
+$2.45M
4
Millennium Management
Millennium Management
New York
+$2.04M
5
Citadel Advisors
Citadel Advisors
Florida
+$1.9M

Top Sellers

1
Renaissance Technologies
Renaissance Technologies
New York
-$1.85M
2
Citigroup
Citigroup
New York
-$1.78M
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$1.44M
4
BlackRock
BlackRock
New York
-$1.4M
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$1.13M
Name Holding Trade Value Shares
Change 		Change in
Stake
AllianceBernstein
26
AllianceBernstein
Tennessee
$1.04M +$218K +35,500 +24%
PI
27
Putnam Investments
Massachusetts
$995K +$540K +88,028 +99%
UBS Group
28
UBS Group
Switzerland
$971K -$1.12M -181,957 -51%
T. Rowe Price Associates
29
T. Rowe Price Associates
Maryland
$926K -$161K -26,281 -14%
Marshall Wace
30
Marshall Wace
United Kingdom
$861K -$554K -90,237 -37%
Jane Street
31
Jane Street
New York
$840K +$751K +122,403 +450%
CCA
32
Clearwater Capital Advisors
Illinois
$830K +$45K +7,340 +5%
Wells Fargo
33
Wells Fargo
California
$748K +$59.2K +9,644 +8%
EMG
34
ETF Managers Group
New Jersey
$711K +$3.02K +492 +0.4%
Allspring Global Investments
35
Allspring Global Investments
North Carolina
$701K -$21.8K -3,556 -3%
CSS
36
Cubist Systematic Strategies
Connecticut
$695K +$644K +105,010 +556%
ASN
37
Advisory Services Network
Georgia
$636K +$695K +113,299 New
Fidelity Investments
38
Fidelity Investments
Massachusetts
$614K +$671K +109,434 New
UBS AM
39
UBS AM
Illinois
$566K – – –
California State Teachers Retirement System (CalSTRS)
40
California State Teachers Retirement System (CalSTRS)
California
$543K -$38.9K -6,334 -6%
MIC
41
Meridian Investment Counsel
California
$541K – – –
D.E. Shaw & Co
42
D.E. Shaw & Co
New York
$534K -$1.44M -235,233 -71%
Citigroup
43
Citigroup
New York
$523K -$1.78M -290,323 -76%
RhumbLine Advisers
44
RhumbLine Advisers
Massachusetts
$494K -$13.2K -2,155 -2%
State of Wisconsin Investment Board
45
State of Wisconsin Investment Board
Wisconsin
$485K – – –
GCP
46
GSA Capital Partners
United Kingdom
$467K -$283K -46,056 -36%
Los Angeles Capital Management
47
Los Angeles Capital Management
California
$359K – – –
WPA
48
Winning Points Advisors
Florida
$339K +$369K +60,126 New
SFFS
49
Stonehage Fleming Financial Services
Jersey
$336K +$368K +60,000 New
Bank of America
50
Bank of America
North Carolina
$314K -$652K -106,291 -66%
1
2
3 4 5

IBRX Hedge Fund Activity: Q1 2022 in Review

149 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q1 2022, worth a combined $200M — down 4.6% from $209M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new IBRX positions and 20 closed out — a net gain of 9 holders — while 44 added to existing stakes and 39 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $3.93M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $1.85M sold.

  • 149 institutional investors held ImmunityBio (IBRX) as of Q1 2022, up from 141 in Q4 2021.
  • Funds reported $200M of ImmunityBio stock for Q1 2022, down 4.6% quarter-over-quarter.
  • 29 funds opened new ImmunityBio positions in Q1 2022 and 20 closed out, a net change of +9 holders.
  • The largest ImmunityBio buyer in Q1 2022 was Morgan Stanley, an estimated $3.93M added.
  • The largest ImmunityBio seller in Q1 2022 was Renaissance Technologies, an estimated $1.85M sold.

Based on aggregated 13F filings for Q1 2022.